1[2]Devogelaer JP,Broll H,Correa-Rotter R,et al. Oral alendronate induces progressive increases in bone mass of the spine,hip,and total body over 3 years in postmenopausal women with osteoporosis. Bone, 1996,18:141-150.
2[4]Lutchman EC,Hardwick TA.Longitudinal study of urinary hydroxyl-pyridinium cross-links and growth in healthy infants:higher values with breastfeeding and after daytime sleep. Exp Clin Endocrinol Diabetes, 1998,106:51-56.
1Hamann C, Kirschner S, Gunther KP, et al. Bone, sweet bone - Osteoporotic fractures in diabetes mellitus. Nature Reviews Endocrinology, 2012, 8: 297-305.
2Ikeda T, Manabe H, Iwata K. Clinical significance of alendronate in postmenopausal type 2 diabetes meUitus. Diabetes Metab, 2004, 30: 355-358.
3Dagdelen S, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther, 2007, 24: 1314-1320.
4Iwamoto J, Sato Y, Uzawa M, et al. Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res Clin Praet, 2011, 93: 166-173.
5Keegan TH, Schwartz AV, Bauer DC, et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care, 2004, 27: 1547-1553.
6Vestergaard P. Risk of ne,aly diagnosed type 2 diabetes is reduced in users of alendronate. Caleif Tissue Int, 2011, 89:265-270.
7Iwamoto ], Sato Y, Uzawa M, et al. Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study. Drags Aging, 2012, 29: 133-142.
8Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausa| osteoporotie women. Phase Ⅲ Osteoporosis Treatment Study Group. J Clin Endocrinol Metab, 2000, 85: 3109-3115.
9Murad MH, Drake MT, Mullan RJ, et al. Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab, 2012,92:3081-3094.
10Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtroehanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab, 2010, 95: 5258-5265.
